GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Psycheceutical Bioscience BWVI · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 27 Oct 2026, in USD

At a glance

Figures in USD, from our data supplier.

FY2022

Revenue

—

FY2014FY2022

Net income

−$17.0m

FY2014FY2022

Free cash flow

−$3.5m

FY2014FY2022

Shareholders' equity

−$135,097

FY2014FY2022

Income statement

Fiscal years

FY2022FY2021FY2020FY2019FY2017FY2016FY2015FY2014
Revenue——$83,779$104,271$75,687$108,257$480,839$77,360
Research and development$661,095———————
Operating income−$11.4m−$1.4m−$135,100−$498,880−$426,770−$453,870−$1.6m−$857,919
Net income−$17.0m−$1.4m−$113,620−$529,427−$581,731−$763,326−$1.6m−$887,112
Diluted earnings per share-0.07-0.02-0.00-0.00-0.01-0.01-0.01-0.00

Balance sheet

At each fiscal year end

FY2022FY2021FY2020FY2019FY2017FY2016FY2015FY2014
Total assets$2.3m$327,323$1.2m$1.2m$194,028$104,099$445,073$1.1m
Cash and short-term investments$2.0m$327,323$8,399—$44,010$4,540$135,208—
Total liabilities$2.4m$264,380$1.2m$1.2m$1.9m$1.9m$2.2m$2.5m
Debt$51,550$250,000$1.1m$1.1m$1.9m$1.9m$2.2m$1.4m
Shareholders' equity−$135,097$62,943−$1.0m−$919,975−$2.6m−$2.7m−$2.8m−$1.4m
Shares outstanding259m71m69m276m51m139m276m276m

Cash flow

Fiscal years

FY2022FY2021FY2020FY2019FY2017FY2016FY2015FY2014
Cash from operations−$3.5m−$869,707−$34,457−$368,431−$213,565−$261,978−$587,953−$364,882
Capital spending−$1−$3−$3−$35,529−$72,336−$26,509−$36,853−$32,733
Free cash flow−$3.5m−$869,710−$34,460−$403,960−$285,901−$288,487−$624,806−$397,615

Latest quarters

By quarter end

Sept 2023Jun 2023Mar 2023Sept 2022Jun 2022Mar 2022Dec 2021Sept 2021
Revenue—————$102,000—$450
Operating income−$2.9m−$1.9m−$3.6m−$893,920−$1.0m−$704,790−$38,340−$89,170
Net income−$2.9m−$1.9m−$3.6m−$892,272−$1.0m−$709,110−$38,341−$89,173
Diluted earnings per share-0.01-0.01-0.01-0.00-0.00-0.00-0.00-0.00
Cash from operations——−$1.0m−$1.0m————
Total assets$1.4m$1.1m$1.5m$4.3m$5.2m$1.8m$1.1m$1.1m
Cash and short-term investments$462,343$190,690$662,738$2.8m$3.8m$722,849$28,427$4,589
Debt$618,399$576,550$51,550———$34,277$34,277
Shareholders' equity−$2.9m−$592,519−$966,525$4.3m$5.1m$1.7m−$25,355$12,986

Growth per year

Compound annual rate

3 years5 years10 years
Operating income183.4%92.8%34.4%
Net income217.7%96.4%—

Valuation history

At each fiscal year end

FY2018
Price to sales0.0

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return9500%-56%-58%-43%2469%-48%3%-47%235%821%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.